FDAmanufacturing / CMC84% confidence
Phase 1 IND Chemistry, Manufacturing, and Controls Flexibilities
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable manufacturing / CMC decision relevant to pharmaceutical manufacturers; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Regulatory Affairs · Drug Manufacturing
- Sub-indication
- General
Related signal: FDA Proposes Streamlined Registration for Distributed Drug Manufacturing